Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (1798)	2/20/1999 11:13:00 AM
From: AJAG	Respond to of 10280

No one on this thread has mentioned the explosive growth which is built into the country's demographics for products like Prozac and the non-sedating antihistamines. I happen to be a 50 year old baby boomer who is taking Claritin. I know many people my age who have recently started taking Prozac or Zoloft. In addition, allergy problems experienced in youth often return in middle age. There are 78 million people who will reach 50 years of age in the next decade and the boomers are used to taking drugs for their ailments. Sepracor's Prozac II and Claritin II do not have to get huge market share to make the company a lot of money. Even if someone comes out with a better antidepressant or antihistamine, these two drugs have a huge "installed base" of satisfied users who won't switch to an entirely different product. PS- I think if you go back and research it, you will find that many pundits said Amgen was wildly overpriced in the early 1990's when the market cap was 2 billion. Now its 34 billion!